7 completed. 7 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 7 |
| Phase 2 | 2 | Completed 2 |
Follow Speech Disorders: new trials by email Literature Review of Speech Disorders trials Research Report on Speech Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brain Correlates of Multimodal Rehabilitation in Chronic Post-stroke Aphasia Donepezil, Intensive-Language Action Therapy, Transcranial direct current stimulation - Aphasia, Stroke | Phase 3 | Completed | University of Malaga | 20 | 2019-01-08 | 2020-11-05 |
| Use of Local Intraoperative Steroid in MIS TLIF Methylprednisolone, Dexamethasone - Dysphasia | Phase 3 | Completed | Rush University Medical Center | 105 | 2015-11-13 | 2020-11-20 |
| AM-111 in the Treatment of Acute Inner Ear Hearing Loss Placebo, AM-111 0.4 mg/ml, AM-111 0.8 mg/ml - Hearing Loss | Phase 3 | Completed | Auris Medical AG | 256 | 2015-11-01 | 2023-09-14 |
| A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering pagoclone, placebo - Stuttering | Phase 2 / Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 321 | 2009-02-01 | 2012-08-28 |
| Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia Melodic Intonation Therapy, Speech-Repetition-Therapy - Aphasia, Stroke | Phase 3 | Completed | Beth Israel Deaconess Medical Center | 30 | 2008-02-01 | 2020-09-21 |
| Augmenting Language Therapy for Aphasia: Levodopa levodopa/carbidopa, Placebo comparator - Nonfluent Aphasia, Stroke | Phase 2 / Phase 3 | Completed | Shirley Ryan AbilityLab | 36 | 2007-10-01 | 2013-12-25 |
| Treatment of Childhood Social Phobia Social Effectiveness Therapy for Children (SET-C), Fluoxetine, Pill Placebo - Social Phobia | Phase 3 | Completed | University of Central Florida | 139 | 2001-04-01 | 2013-08-01 |
Aphasia (4) · Stroke (3) · Aphasia, Broca (1) · Brain Infarction (1) · Brain Ischemia (1) · Cerebral Infarction (1) · Cerebrovascular Disorders (1) · Deafness (1) · Ear Diseases (1) · Hearing Disorders (1) · Hearing Loss (1) · Hearing Loss, Sensorineural (1) · Hearing Loss, Unilateral (1) · Ischemic Stroke (1)
Communication Disorders (7) · Language Disorders (7) · Nervous System Diseases (7) · Neurobehavioral Manifestations (7) · Neurologic Manifestations (7) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (6) · Brain Diseases (3) · Cardiovascular Diseases (3) · Central Nervous System Diseases (3) · Vascular Diseases (3) · Cerebrovascular Disorders (2) · Anxiety Disorders (1) · Infarction (1)
D-JNKI-1 (1) · Dexamethasone (1) · Donepezil (1) · Fluoxetine (1) · Methylprednisolone (1) · Transcranial Direct Current Stimulation (1) · carbidopa, levodopa drug combination (1) · pagoclone (1)
Auris Medical AG (1) · Beth Israel Deaconess Medical Center (1) · Endo USA Inc., a Keenova Therapeutics Company (1) · Rush University Medical Center (1) · Shirley Ryan AbilityLab (1) · University of Central Florida (1) · University of Malaga (1)
United States (4) · Bulgaria (1) · Spain (1)
Andrea Norton, BM (1) · Gottfried Schlaug, MD, PhD (1) · Kern Singh, MD (1) · Marcelo L Berthier, MD, PhD (1)
PMID 18030084, PMID 19673813, PMID 20013046, PMID 21197418, PMID 21391024, PMID 30497132, PMID 35433325
R01DC008796 (1), R01MH053703 (1)